Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). [electronic resource]
Producer: 20090707Description: 199-205 p. digitalISSN:- 1095-6859
- Adult
- Aged
- Antineoplastic Agents, Alkylating -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Busulfan -- adverse effects
- Disease-Free Survival
- Female
- Humans
- Infusions, Intravenous
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Organoplatinum Compounds -- administration & dosage
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Prospective Studies
- Survival Rate
- Topotecan -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.